Thr222
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr222  -  MKK3 (human)

Site Information
LVDsVAKtMDAGCKP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448277

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 ) , mutation of modification site ( 8 ) , phospho-antibody ( 5 , 7 ) , western blotting ( 5 , 7 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , gastric cancer ( 4 ) , gastric carcinoma ( 4 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
MLK3 (human) ( 7 )
Kinases, in vitro:
MKK3 (human) ( 6 )
Putative upstream phosphatases:
PPP2CA (human) ( 5 )
Phosphatases, in vitro:
PPP2CA (human) ( 5 )
Treatments:
sorbitol ( 7 )

Downstream Regulation
Effects of modification on MKK3:
activity, induced ( 5 ) , enzymatic activity, induced ( 6 , 8 )
Effects of modification on biological processes:
cell cycle regulation ( 5 ) , transcription, induced ( 8 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

3

Rikova K (2010) CST Curation Set: 9456; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

4

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

5

Prickett TD, Brautigan DL (2007) Cytokine activation of p38 mitogen-activated protein kinase and apoptosis is opposed by alpha-4 targeting of protein phosphatase 2A for site-specific dephosphorylation of MEK3. Mol Cell Biol 27, 4217-27
17438131   Curated Info

6

Deacon K, Blank JL (1997) Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)/c-Jun NH2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3. MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo. J Biol Chem 272, 14489-96
9162092   Curated Info

7

Tibbles LA, et al. (1996) MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. EMBO J 15, 7026-35
9003778   Curated Info

8

Raingeaud J, et al. (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 16, 1247-55
8622669   Curated Info